Genetics Of Autoimmunity In Type I Diabetes
Part of paid clinical trials in Milwaukee, Wisconsin.
- Sponsor
- Medical College of Wisconsin
- Study ID
- NCT03648918
- Status
- Recruiting
Conditions
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Type1 Diabetes Mellitus
- Type1diabetes
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Blood Collection — OTHERBlood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
Study Details
The purpose of this study is to gain more information about the step-by-step process that causes someone to develop type 1 diabetes. Scientists think that a person's own immune system, directed by genetic and environmental factors play a major role in its development. Participation involves a blood draw, a brief medical history questionnaire and measurements of height and weight. Some participants will be asked to return for annual follow-up visits for 10 years.
Key Dates
- Start date
- Aug 31, 2001
- Status verified
- Mar 2026
- Primary completion
- Jan 31, 2050
- Completion
- Jan 31, 2050
Study Design
- Enrollment
- 4,000 participants (estimated)
Primary Outcome Measure
Onset of Type 1 diabetes [ Time Frame: Up to 10 years ]
Central Contacts
- Martin Hessner, PhD414-955-4903
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 |
Find similar trials in Milwaukee, WI
By condition
By specialty
By research site
Related Studies
- A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 DiabetesPHASE3 · Recruiting · Vertex Pharmaceuticals Incorporated · Duarte, California
- PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility StudyNot Yet Recruiting · Medical College of Wisconsin · Milwaukee, Wisconsin
- Leveraging Artificial Intelligence to Prevent Vision Loss From DiabetesNot Yet Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesPHASE3 · Recruiting · Novo Nordisk A/S · Cullman, Alabama